137 Startups
  • Sector
  • Participated in
  • Year of participation

IS-Diagnostics

  • 2010
  • Diagnostics
  • Other
The next generation of clinical diagnostics

JETA molecular

  • 2016
  • Enabling Technology
  • Other
Design, development and commercialization of noninvasive reagent and software solutions for transplant monitoring

Karveel

  • 2015
  • Therapeutics
  • Venture Challenge
To develop early-stage antibiotic lead compounds discovered by researchers at Utrecht University. Specifically, we aim to target clinically-relevant pathogenic bacteria that have become resistant to first-line antibiotics.

Khondrion

  • 2010
  • Other
  • Therapeutics
Khondrion is a clinical stage pharmaceutical company focusing on the development of treatments for mitochondrial (-related) diseases and conditions

KimerDx

  • 2013
  • Diagnostics
  • Venture Challenge
Molecular diagnostics products for chimerisme monitoring

Levels Diagnostics

  • 2019
  • Diagnostics
  • Venture Challenge
Levels Dx is using activated immune cells as biomarkers to allow an accurate diagnosis of a bacterial infection in patients. The Rapid Diagnostic Tool (RDT) will provide accurate results within minutes and is portable.

Lumox

  • 2023
  • Therapeutics
  • Venture Challenge
We have developed a new, potent anticancer therapy with minimal side effects, as it has two levels of selectivity: a nanobody that directs a light-activatable drug to cancer cells, and light locally applied at the tumor to activate the drug.

Mantis Therapeutics

  • 2016
  • Therapeutics
  • Venture Challenge
Developing an innovative targeted immunotherapy against cancer using remote controlled conditional attenuated bacteria.

MAXAM Medical

  • 2009
  • Medical Device
  • Venture Challenge
Diagnostic and treatment device for pelvic floor dysfunctions, such as prolapse, micturition, defecation and urinary and faecal incontinence

MedicalVR

  • 2020
  • Medical Device
  • Venture Challenge
MedicalVR’s PulmoVR innovation enables thoracic surgeons to cure patients with lung cancer by preventing the unnecessary removal of healthy lung tissue, resulting in a ‘lung-sparing surgical procedure’ for lung cancer.